Women’s Health Dx
Positive Clinical Validation Data for PreTRM® Test Presented at the Society for Maternal-Fetal Medicine’s 36th Annual Pregnancy Meeting
Sera Prognostics, Inc., a women’s healthcare company, today announced that results from the 5,501-patient Proteomic Assessment of Preterm Risk (PAPR) study validate the newly available PreTRM® test, which accurately and objectively predicts spontaneous preterm birth (sPTB), in pregnant women whose blood is drawn for analysis as early as 19 weeks of pregnancy. The data were presented at the Society for Maternal-Fetal Medicine’s 36th Annual Pregnancy Meeting in Atlanta, Georgia. Read More >
Sera Prognostics Announces Clinical Study Data Selected for Presentation at the Society for Maternal-Fetal Medicine’s 36th Annual Pregnancy Meeting
Sera Prognostics, Inc. announced that findings from the 5,501 patient Proteomic Assessment of Preterm Risk (PAPR) study will be reported in an oral presentation during the Society for Maternal-Fetal Medicine’s (SMFM) 36th Annual Pregnancy Meeting™ in Atlanta, February 1-6, 2016. Read More >
Sera Prognostics to Present at 34th Annual J.P. Morgan Healthcare Conference
Sera Prognostics, Inc. today announced that Gregory C. Critchfield, M.D., M.S., Chairman and Chief Executive Officer, will present at the upcoming J.P. Morgan Healthcare Conference. Read More >
Providing An Individualized Risk Assessment to Predict and Manage premature birth, preeclampsia, and other Pregnancy Complications
Sera Prognostics is focused on improving maternal and infant health by developing simple blood tests to predict the risks of pregnancy complications. Our initial focus is on one of the most serious pregnancy complications—preterm birth—which affects 11.4% of pregnancies in the U.S. alone.
Early and accurate prediction of risk for pregnancy complications may help pregnant women and their doctors take action and make a difference by putting early interventions in place. Learn about the PreTRM™ Test for Risk Management.